MCID: ORL007
MIFTS: 61

Oral Cavity Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oral Cavity Cancer

MalaCards integrated aliases for Oral Cavity Cancer:

Name: Oral Cavity Cancer 12 15
Malignant Neoplasm of Anterior Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Floor of Mouth 12
Malignant Tumor of Anterior Floor of Mouth 12
Malignant Tumor of Lateral Floor of Mouth 12
Malignant Tumor of the Floor of the Mouth 12
Malignant Neoplasm of Floor of Mouth 12
Malignant Tumor of Floor of Mouth 6
Neoplasm of the Oral Cavity 29
Malignant Neoplasm of Mouth 73
Oral Cavity Carcinoma 73

Classifications:



Summaries for Oral Cavity Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the oral cavity.

MalaCards based summary : Oral Cavity Cancer, also known as malignant neoplasm of anterior portion of floor of mouth, is related to salivary gland cancer and leukoplakia. An important gene associated with Oral Cavity Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include the oral cavity, salivary gland and tongue, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Decreased viability with paclitaxel

Related Diseases for Oral Cavity Cancer

Diseases in the Oral Cavity Cancer family:

Oral Cavity Carcinoma in Situ

Diseases related to Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 salivary gland cancer 32.4 CASP8 EGFR ERBB2 PTEN
2 leukoplakia 31.1 CYP1A1 GSTM1 GSTT1
3 lip and oral cavity cancer 12.3
4 breast intraductal proliferative lesion 11.1 EGFR ERBB2
5 oral squamous cell carcinoma 11.0
6 geographic tongue 10.9 EGFR TNFRSF10B VEGFA
7 primary peritoneal carcinoma 10.9 EGFR ERBB2 VEGFA
8 intracystic papillary adenoma 10.9 EGFR ERBB2
9 breast carcinoma in situ 10.9 EGFR ERBB2 VEGFA
10 pharynx cancer 10.9 EGFR GSTM1 VEGFA
11 hearing loss, noise-induced 10.9 GSTM1 GSTT1
12 oral submucous fibrosis 10.9 CYP1A1 GSTM1 GSTT1
13 sister chromatid exchange, frequency of 10.8 ALDH2 GSTM1 GSTT1
14 progesterone-receptor negative breast cancer 10.8 EGFR ERBB2
15 breast squamous cell carcinoma 10.8 EGFR ERBB2 PIK3CA
16 adenosquamous cell lung carcinoma 10.8 EGFR ERBB2 PIK3CA
17 breast scirrhous carcinoma 10.8 EGFR ERBB2
18 mucinous stomach adenocarcinoma 10.8 PTEN VEGFA
19 oral cancer 10.8 CYP1A1 EGFR GSTM1 GSTT1
20 adult hepatocellular carcinoma 10.8 CASP8 PIK3CA
21 ovarian cancer 1 10.7 ERBB2 PIK3CA VEGFA
22 serous cystadenocarcinoma 10.7 ERBB2 PIK3CA VEGFA
23 estrogen-receptor positive breast cancer 10.7 EGFR ERBB2 PIK3CA
24 thyroid hurthle cell adenoma 10.7 PIK3CA PTEN
25 acneiform dermatitis 10.7 CYP1A1 EGFR ERBB2 PIK3CA
26 cystadenocarcinoma 10.7 ERBB2 PIK3CA VEGFA
27 grade iii astrocytoma 10.7 EGFR PTEN VEGFA
28 malignant ovarian surface epithelial-stromal neoplasm 10.7 EGFR ERBB2 PIK3CA VEGFA
29 ovary epithelial cancer 10.7 EGFR ERBB2 PIK3CA VEGFA
30 ovarian serous cystadenocarcinoma 10.7 ERBB2 PIK3CA VEGFA
31 endometrial adenocarcinoma 10.6 EGFR ERBB2 PTEN VEGFA
32 pancreas adenocarcinoma 10.6 EGFR ERBB2 PIK3CA VEGFA
33 acute lymphocytic leukemia 10.6 GSTM1 GSTT1 MCL1
34 bladder squamous cell carcinoma 10.6 ERBB2 PIK3CA PTEN
35 tobacco addiction 10.6 ALDH2 GSTM1 GSTT1
36 breast adenocarcinoma 10.5 CASP8 CYP1A1 EGFR ERBB2 PIK3CA
37 uterine carcinosarcoma 10.5 EGFR ERBB2 PIK3CA PTEN
38 renal cell carcinoma, papillary, 1 10.5 ERBB2 PIK3CA PTEN
39 cell type cancer 10.5 EGFR ERBB2 PTEN SOX2 VEGFA
40 cowden syndrome 1 10.5 EGFR PTEN
41 basal cell carcinoma 10.4 CYP1A1 GSTM1 GSTT1 PTEN
42 bladder cancer 10.4 EGFR ERBB2 GSTM1 GSTT1 VEGFA
43 female reproductive organ cancer 10.4 EGFR ERBB2 PIK3CA PTEN VEGFA
44 transitional cell carcinoma 10.4 EGFR ERBB2 PTEN
45 gastrointestinal system cancer 10.3 EGFR ERBB2 PIK3CA PTEN VEGFA
46 lung cancer susceptibility 3 10.3 CASP8 CYP1A1 EGFR ERBB2 PIK3CA VEGFA
47 glioblastoma multiforme 10.3 EGFR ERBB2 PIK3CA PTEN VEGFA
48 adenocarcinoma 10.3 EGFR ERBB2 PIK3CA PTEN VEGFA
49 larynx cancer 10.3 EGFR GSTM1 GSTT1
50 glioma 10.3 EGFR ERBB2 PIK3CA PTEN VEGFA

Comorbidity relations with Oral Cavity Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oral Cavity Cancer:



Diseases related to Oral Cavity Cancer

Symptoms & Phenotypes for Oral Cavity Cancer

GenomeRNAi Phenotypes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 EGFR ERBB2 GSTM1 PTEN VEGFA
2 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 FADD
3 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Oral Cavity Cancer:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.42 ALDH2 CYP1A1 EGFR CASP8 FADD LIN28B
2 cardiovascular system MP:0005385 10.4 CYP1A1 EGFR CASP8 FADD LIN28B ERBB2
3 homeostasis/metabolism MP:0005376 10.37 EGFR CASP8 CYP1A1 ALDH2 FADD LIN28B
4 cellular MP:0005384 10.36 EGFR CASP8 ALDH2 HSP90B1 FADD ERBB2
5 mortality/aging MP:0010768 10.36 ALDH2 CYP1A1 EGFR CASP8 FADD LIN28B
6 endocrine/exocrine gland MP:0005379 10.34 CASP8 ALDH2 CYP1A1 EGFR FADD ERBB2
7 embryo MP:0005380 10.31 CASP8 EGFR FADD LIN28B ERBB2 HSP90B1
8 immune system MP:0005387 10.29 EGFR CASP8 CYP1A1 ALDH2 HSP90B1 FADD
9 hematopoietic system MP:0005397 10.28 CASP8 EGFR CYP1A1 ALDH2 HSP90B1 FADD
10 integument MP:0010771 10.19 EGFR CASP8 ALDH2 ERBB2 PIK3CA PTEN
11 digestive/alimentary MP:0005381 10.18 EGFR FADD ERBB2 SHOX2 PTEN TLR2
12 nervous system MP:0003631 10.18 EGFR CASP8 ALDH2 FADD LIN28B GDF15
13 liver/biliary system MP:0005370 10.13 EGFR CASP8 CYP1A1 ALDH2 FADD GDF15
14 muscle MP:0005369 10.13 EGFR CASP8 FADD LIN28B ERBB2 SOX2
15 neoplasm MP:0002006 10.06 CASP8 ALDH2 EGFR ERBB2 SOX2 PTEN
16 normal MP:0002873 9.91 EGFR CYP1A1 ERBB2 LIN28B MCL1 PTEN
17 no phenotypic analysis MP:0003012 9.87 CYP1A1 HSP90B1 EGFR FADD PIK3CA SOX2
18 renal/urinary system MP:0005367 9.7 CASP8 ALDH2 EGFR GDF15 PTEN TLR2
19 respiratory system MP:0005388 9.5 CASP8 ERBB2 EGFR PTEN VEGFA TLR2
20 skeleton MP:0005390 9.32 EGFR ALDH2 FADD ERBB2 SHOX2 PIK3CA

Drugs & Therapeutics for Oral Cavity Cancer

Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 387)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
2
Racepinephrine Approved Phase 4,Phase 2,Phase 1 329-65-7 838
3
Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
4
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
5
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
6
Dobutamine Approved Phase 4,Not Applicable 34368-04-2 36811
7
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
8
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
9
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
10
Pentetic acid Approved Phase 4 67-43-6
11
protease inhibitors Phase 4,Phase 2,Phase 3
12 Respiratory System Agents Phase 4,Phase 2,Not Applicable
13 Adrenergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
14 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
15 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Not Applicable
16 Chelating Agents Phase 4,Not Applicable,Early Phase 1
17 Adrenergic beta-Agonists Phase 4,Phase 2,Not Applicable
18 Mydriatics Phase 4,Phase 2
19 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
20 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
21 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
22 Vasoconstrictor Agents Phase 4,Phase 2,Phase 1,Not Applicable
23 Anti-Asthmatic Agents Phase 4,Phase 2
24 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Epinephryl borate Phase 4,Phase 2,Phase 1
26 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Radiopharmaceuticals Phase 4,Phase 1,Phase 2,Not Applicable
29 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
30 Bronchodilator Agents Phase 4,Phase 2
31 Dopamine agonists Phase 4
32 Central Nervous System Stimulants Phase 4,Phase 3,Not Applicable
33 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Technetium Tc 99m Pentetate Phase 4
35 Technetium Tc 99m Sulfur Colloid Phase 4,Not Applicable
36 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
37 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
38 Nicotinic Agonists Phase 4,Not Applicable
39 Dextrans Phase 4
40 Dopamine Agents Phase 4,Phase 2
41 Vasodilator Agents Phase 4,Not Applicable
42 Dopamine Uptake Inhibitors Phase 4,Phase 2
43 Plasma Substitutes Phase 4
44 Anticoagulants Phase 4,Not Applicable
45 Antidepressive Agents Phase 4,Phase 3,Phase 2
46 Antidepressive Agents, Second-Generation Phase 4,Phase 2
47 Psychotropic Drugs Phase 4,Phase 3,Phase 2
48 Blood Substitutes Phase 4
49 Calcium, Dietary Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 diuretics Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 545)
# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
2 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
3 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
5 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
6 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
7 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
8 Aliskiren Study of Safety and Efficacy in Senior Hypertensives Withdrawn NCT01922141 Phase 4 Aliskiren;Amlodipine;Ramipril;Hydrochlorothiazide
9 Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Unknown status NCT00655421 Phase 3
10 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
11 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
12 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
13 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
14 Trial of IIb Preserving Neck Dissection Unknown status NCT00847717 Phase 3
15 The Feasibility of Dexmedetomidine for Awake Fiberoptic Nasal Intubation Unknown status NCT00815893 Phase 2, Phase 3 dexmedetomidine;Normal Saline 0.9%;propofol 1%
16 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
17 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
18 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
19 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
20 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
21 Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
22 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Completed NCT01265849 Phase 3
23 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
24 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
25 Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Completed NCT00201279 Phase 3 13-cis Retino Acid
26 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
27 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
28 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
29 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
30 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
31 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
32 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
33 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
34 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
35 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
36 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
37 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
38 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
39 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
40 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
41 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
42 The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome Completed NCT01414790 Phase 3
43 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Recruiting NCT00964977 Phase 3
44 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Recruiting NCT03237325 Phase 3 SGX942;Placebo
45 Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers Recruiting NCT02868151 Phase 2, Phase 3 Ascorbic Acid;Zinc acetate
46 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
47 Erlotinib Prevention of Oral Cancer (EPOC) Active, not recruiting NCT00402779 Phase 3 Erlotinib;Placebo
48 IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
49 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
50 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel

Search NIH Clinical Center for Oral Cavity Cancer

Genetic Tests for Oral Cavity Cancer

Genetic tests related to Oral Cavity Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Oral Cavity 29

Anatomical Context for Oral Cavity Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Oral Cavity Cancer:

19
The Oral Cavity

MalaCards organs/tissues related to Oral Cavity Cancer:

41
Salivary Gland, Tongue, Lymph Node, Lung, Skin, Brain, Testes

Publications for Oral Cavity Cancer

Articles related to Oral Cavity Cancer:

(show top 50) (show all 301)
# Title Authors Year
1
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. ( 29706184 )
2018
2
Association of Time between Surgery and Adjuvant Therapy with Survival in Oral Cavity Cancer. ( 29313448 )
2018
3
Detection of surgical margins in oral cavity cancer: the role of dynamic optical contrast imaging. ( 29517537 )
2018
4
Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis. ( 29761306 )
2018
5
Expression profiles of selected genes in tumors and matched surgical margins in oral cavity cancer: Do we have to pay attention to the molecular analysis of the surgical margins? ( 29790687 )
2018
6
Locoregionally advanced oral cavity cancer: A propensity-score matched analysis on overall survival with emphasis on the impact of adjuvant radiotherapy. ( 29665118 )
2018
7
The influence of insurance status on treatment and outcomes in oral cavity cancer: an analysis on 46,373 patients. ( 29655817 )
2018
8
MR lymphography for sentinel lymph node detection in patients with oral cavity cancer: Preliminary clinical study. ( 29633413 )
2018
9
The influence of marital status on survival for patients aged 65 years and younger with oral cavity cancer. ( 29685504 )
2018
10
The effectiveness of a saline mouth rinse regimen and education programme on radiation-induced oral mucositis and quality of life in oral cavity cancer patients: A randomised controlled trial. ( 29315944 )
2018
11
Effects of a swallowing exercise education program on dysphagia-specific health-related quality of life in oral cavity cancer patients post-treatment: a randomized controlled trial. ( 29546525 )
2018
12
Opioid prescribing practices in patients undergoing surgery for oral cavity cancer. ( 29756393 )
2018
13
Genetic analysis of surgical margins in oral cavity cancer. ( 29341160 )
2018
14
Narrow Band Imaging-guided resection of oral cavity cancer decreases local recurrence and increases survival. ( 29480612 )
2018
15
Aberrant DNA methylation of the <i>p16, APC, MGMT, TIMP3</i> and <i>CDH1</i> gene promoters in tumours and the surgical margins of patients with oral cavity cancer. ( 29896273 )
2018
16
Diagnostic Pathway of Oral Cavity Cancer in an Integrated Health Care System. ( 29616906 )
2018
17
Can MR textural analysis improve the prediction of extracapsular nodal spread in patients with oral cavity cancer? ( 29872911 )
2018
18
Detection of cervical lymph node metastasis from oral cavity cancer using a non-radiating, noninvasive digital infrared thermal imaging system. ( 29739969 )
2018
19
High sensitivity and negative predictive value of sentinel lymph node biopsy in a retrospective early stage oral cavity cancer cohort in the Northern Netherlands. ( 29575685 )
2018
20
Untreated oral cavity cancer: Long-term survival and factors associated with treatment refusal. ( 28865100 )
2017
21
Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer. ( 28880746 )
2017
22
Recent Trends in Oral Cavity Cancer Research Support in the United States. ( 28033064 )
2017
23
Comparison of facility type outcomes for oral cavity cancer: Analysis of the national cancer database. ( 28671267 )
2017
24
Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis. ( 28426848 )
2017
25
Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. ( 28806994 )
2017
26
Coinfection with Epstein-Barr Virus (EBV), Human Papilloma Virus (HPV) and Polyoma BK Virus (BKPyV) in Laryngeal, Oropharyngeal and Oral Cavity Cancer. ( 29257122 )
2017
27
Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. ( 28797467 )
2017
28
Treatment outcome of advance staged oral cavity cancer: concurrent chemoradiotherapy compared with primary surgery. ( 28321535 )
2017
29
What additional treatment is indicated for oral cavity cancer with isolated perineural invasion? ( 28349551 )
2017
30
Estimating Survival After Salvage Surgery for Recurrent Oral Cavity Cancer. ( 28448645 )
2017
31
Factors associated with continued smoking after treatment of oral cavity cancer: An age and survival time-matched study. ( 29148210 )
2017
32
Frequency of Depression and its Correlation with Quality of Life of Patients with Oral Cavity Cancer. ( 28883770 )
2017
33
Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer. ( 28838425 )
2017
34
Chronic Opioid Use Following Surgery for Oral Cavity Cancer. ( 28445584 )
2017
35
Prognostic implication of ERCC1 protein expression in resected oropharynx and oral cavity cancer. ( 28645807 )
2017
36
Primary Surgery vs Radiotherapy for Early Stage Oral Cavity Cancer. ( 29256326 )
2017
37
Pathological features and their prognostic impacts on oral cavity cancer patients among different subsites - A singe institute's experience in Taiwan. ( 28785002 )
2017
38
Comparison of Selected Protein Levels in Tumour and Surgical Margin in a Group of Patients with Oral Cavity Cancer. ( 28421310 )
2017
39
Influence of time interval from diagnosis to treatment on survival for oral cavity cancer: A nationwide cohort study. ( 28388649 )
2017
40
Quality Metrics in Oral Cavity Cancer-Developing Standards for Optimal Lymph Node Yield. ( 28715525 )
2017
41
Conditional relative survival of oral cavity cancer: Based on Korean Central Cancer Registry. ( 28797465 )
2017
42
Surgical site infections following oral cavity cancer resection and reconstruction is a risk factor for plate exposure. ( 28390434 )
2017
43
Quality of Life of Patients with Oral Cavity Cancer. ( 28484351 )
2017
44
Individualized risk prediction of outcomes for oral cavity cancer patients. ( 27939002 )
2016
45
Electronic Cigarette: Role in the Primary Prevention of Oral Cavity Cancer. ( 27773997 )
2016
46
Impact of microsatellite alteration in surgical margins on local recurrence in oral cavity cancer patients. ( 27430224 )
2016
47
Neck dissection and stroke in patients with oral cavity cancer: A population-based cohort study. ( 27439202 )
2016
48
CT Accuracy of Extrinsic Tongue Muscle Invasion in Oral Cavity Cancer. ( 28059707 )
2016
49
High-Volume Surgeons Deliver Larger Surgical Margins in Oral Cavity Cancer. ( 26896758 )
2016
50
Human Papilloma Virus in Oral Cavity Cancer and Relation to Change in Quality of Life Following Treatment-a Pilot Study from Northern India. ( 27872524 )
2016

Variations for Oral Cavity Cancer

ClinVar genetic disease variations for Oral Cavity Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
2 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh38 Chromosome 3, 179234296: 179234296
3 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
4 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh38 Chromosome 10, 87933147: 87933147
5 PIK3CA NM_006218.3(PIK3CA): c.3145G> C (p.Gly1049Arg) single nucleotide variant Likely pathogenic rs121913277 GRCh38 Chromosome 3, 179234302: 179234302
6 PIK3CA NM_006218.3(PIK3CA): c.3145G> C (p.Gly1049Arg) single nucleotide variant Likely pathogenic rs121913277 GRCh37 Chromosome 3, 178952090: 178952090

Expression for Oral Cavity Cancer

Search GEO for disease gene expression data for Oral Cavity Cancer.

Pathways for Oral Cavity Cancer

Pathways related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 CASP8 EGFR ERBB2 FADD HSP90B1 MCL1
2
Show member pathways
13.38 EGFR ERBB2 FADD GDF15 PTEN TLR2
3
Show member pathways
13.32 EGFR ERBB2 HSP90B1 MCL1 PIK3CA SOX2
4
Show member pathways
12.81 EGFR ERBB2 HSP90B1 PIK3CA PTEN VEGFA
5
Show member pathways
12.76 CASP8 FADD MCL1 PIK3CA TNFRSF10B
6
Show member pathways
12.74 CASP8 FADD PIK3CA TLR2 TNFRSF10B
7
Show member pathways
12.72 EGFR ERBB2 PIK3CA PTEN VEGFA
8
Show member pathways
12.71 EGFR ERBB2 GSTM1 GSTT1 PIK3CA PTEN
9
Show member pathways
12.68 CASP8 EGFR ERBB2 FADD HSP90B1 MCL1
10
Show member pathways
12.47 CASP8 FADD PIK3CA PTEN TLR2 VEGFA
11
Show member pathways
12.45 EGFR ERBB2 PIK3CA PTEN
12
Show member pathways
12.45 CASP8 EGFR FADD PIK3CA PTEN TNFRSF10B
13
Show member pathways
12.43 EGFR ERBB2 PIK3CA VEGFA
14
Show member pathways
12.4 CASP8 EGFR ERBB2 PIK3CA
15 12.39 EGFR ERBB2 MCL1 PIK3CA PTEN VEGFA
16
Show member pathways
12.28 CASP8 FADD HSP90B1 TLR2
17
Show member pathways
12.24 CASP8 FADD PIK3CA TNFRSF10B
18 12.23 EGFR ERBB2 PIK3CA TLR2 VEGFA
19 12.18 CASP8 FADD GDF15 MCL1 TNFRSF10B
20
Show member pathways
12.1 EGFR ERBB2 PIK3CA PTEN
21 12.09 EGFR ERBB2 HSP90B1 PIK3CA PTEN
22
Show member pathways
12.06 EGFR ERBB2 PIK3CA PTEN
23 12.04 CASP8 EGFR FADD PTEN VEGFA
24 12.04 CASP8 EGFR ERBB2 FADD GSTM1 GSTT1
25 11.94 GSTM1 GSTT1 HSP90B1 PIK3CA VEGFA
26 11.93 HSP90B1 MCL1 SOX2 VEGFA
27 11.89 EGFR GDF15 MCL1 PTEN TNFRSF10B
28 11.86 EGFR ERBB2 PIK3CA VEGFA
29
Show member pathways
11.83 CASP8 EGFR ERBB2 HSP90B1 PIK3CA TLR2
30
Show member pathways
11.82 EGFR ERBB2 VEGFA
31
Show member pathways
11.78 HSP90B1 MCL1 PIK3CA
32
Show member pathways
11.77 CASP8 FADD MCL1
33
Show member pathways
11.73 CYP1A1 GSTM1 GSTT1
34 11.69 EGFR ERBB2 VEGFA
35 11.63 ERBB2 PIK3CA PTEN
36 11.61 EGFR ERBB2 PIK3CA PTEN
37 11.49 CYP1A1 EGFR VEGFA
38 11.46 CASP8 PIK3CA VEGFA
39 11.41 CASP8 FADD TNFRSF10B
40
Show member pathways
11.4 EGFR PIK3CA VEGFA
41 11.3 CASP8 ERBB2 FADD GSTM1 GSTT1 PIK3CA
42 11.25 EGFR ERBB2 PIK3CA
43 11.1 CYP1A1 GSTM1 GSTT1

GO Terms for Oral Cavity Cancer

Cellular components related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.62 CASP8 EGFR FADD TLR2
2 cell body GO:0044297 9.54 CASP8 FADD TLR2
3 cytoplasm GO:0005737 9.53 CASP8 CYP1A1 EGFR ERBB2 FADD GDF15
4 death-inducing signaling complex GO:0031264 9.26 CASP8 FADD
5 CD95 death-inducing signaling complex GO:0031265 9.16 CASP8 FADD
6 ripoptosome GO:0097342 8.96 CASP8 FADD

Biological processes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.93 EGFR ERBB2 HSP90B1 MCL1 PTEN VEGFA
2 regulation of apoptotic process GO:0042981 9.89 CASP8 FADD GDF15 MCL1 TNFRSF10B
3 cytokine-mediated signaling pathway GO:0019221 9.88 HSP90B1 MCL1 PIK3CA SOX2 VEGFA
4 response to lipopolysaccharide GO:0032496 9.85 CASP8 CYP1A1 TLR2 TNFRSF10B
5 response to estradiol GO:0032355 9.83 CASP8 EGFR PTEN
6 response to hypoxia GO:0001666 9.83 CYP1A1 HSP90B1 TLR2 VEGFA
7 positive regulation of MAPK cascade GO:0043410 9.81 EGFR ERBB2 SOX2 TNFRSF10B
8 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.8 CASP8 FADD TNFRSF10B
9 liver development GO:0001889 9.79 CYP1A1 EGFR PIK3CA
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 EGFR PIK3CA VEGFA
11 apoptotic signaling pathway GO:0097190 9.77 CASP8 FADD TNFRSF10B
12 positive regulation of MAP kinase activity GO:0043406 9.74 EGFR ERBB2 VEGFA
13 positive regulation of epithelial cell proliferation GO:0050679 9.73 EGFR ERBB2 VEGFA
14 cell surface receptor signaling pathway GO:0007166 9.72 CASP8 EGFR ERBB2 FADD TNFRSF10B
15 negative regulation of ERBB signaling pathway GO:1901185 9.65 EGFR ERBB2
16 positive regulation of macrophage differentiation GO:0045651 9.64 CASP8 FADD
17 activation of cysteine-type endopeptidase activity GO:0097202 9.64 CASP8 FADD
18 response to arsenic-containing substance GO:0046685 9.63 CYP1A1 PTEN
19 negative regulation of phagocytosis GO:0050765 9.63 PTEN TLR2
20 regulation of necroptotic process GO:0060544 9.61 CASP8 FADD
21 ERBB2 signaling pathway GO:0038128 9.61 EGFR ERBB2 PIK3CA
22 toll-like receptor 3 signaling pathway GO:0034138 9.59 CASP8 FADD
23 death-inducing signaling complex assembly GO:0071550 9.58 CASP8 FADD
24 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.58 CASP8 FADD TNFRSF10B
25 cellular response to mechanical stimulus GO:0071260 9.46 CASP8 EGFR FADD TNFRSF10B
26 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.43 CASP8 FADD TNFRSF10B
27 TRAIL-activated apoptotic signaling pathway GO:0036462 9.37 CASP8 FADD
28 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.13 CASP8 FADD TNFRSF10B
29 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 8.8 CASP8 FADD TNFRSF10B
30 multicellular organism development GO:0007275 10.13 EGFR ERBB2 MCL1 SHOX2 SOX2 TNFRSF10B
31 apoptotic process GO:0006915 10.01 CASP8 FADD MCL1 PTEN TLR2 TNFRSF10B

Molecular functions related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 CASP8 CYP1A1 EGFR ERBB2 FADD GDF15
2 protein heterodimerization activity GO:0046982 9.77 EGFR ERBB2 MCL1 TLR2 VEGFA
3 platelet-derived growth factor receptor binding GO:0005161 9.43 PTEN VEGFA
4 protein phosphatase binding GO:0019903 9.43 EGFR ERBB2 HSP90B1
5 death receptor binding GO:0005123 9.4 CASP8 FADD
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.33 EGFR ERBB2 PIK3CA
7 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.32 EGFR ERBB2
8 death effector domain binding GO:0035877 8.62 CASP8 FADD

Sources for Oral Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....